In vitro Testing, Trials Technology Technology Offers Page 2

IMIM Institut Recerca Hospital del Mar posted this:

Up to date there is not any technology for detecting the risk to suffer atypical fractures related to long-term treatment with bone remodelling inhibitors. The invention will be of usefulness for individualize treatments in patients treated with bone remodelling inhibitors by detecting the individual risk of suffering atypical fractures. The invention is planned to be included into an in-vitro diagnostic tool for the atypical fracture, which will be included into standard disease management protocols and therefore used routinely by physicians prior to and after the prescription of bone remodelling drugs and further osteoporosis drugs. Osteoporosis is a progressive bone disease with a characteristic decrease in bone mass and density which can lead to an increased risk of fracture. There are two types of osteoporosis: •Type 1: most common in women after menopause, named postmenopausal osteoporosis •Type 2: Senile osteoporosis, occurs mostly after age of 75 years and has equally effect in women and in men Based on the WHO diagnostic criteria, approximately 22 million women and 5.5 million men aged between 50 and 84 years had osteoporosis in the European Union (EU) in 2010, whilst osteoporosis can be found in the list of 10 most important diseases named by the WHO. Due to changes in population demography, the number of men and women with osteoporosis might rise from 27.5 million in 2010 to 33.9 million in 2025, corresponding to an increase of 23%. The number of new fractures in the EU in 2010 was estimated at 3,5 million cases, in between these approximately 620.000 hip fractures, 520.000 vertebral fractures, 560.000 forearm fractures and 1.800.000 fractures of i.e. pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum, and other femoral fractures. Two thirds of all fractures occurred in women. In 2010, the number of deaths causally related to fractures was estimated at 43.000. The corresponding cost of osteoporosis in the EU, also in 2010 figures, including pharmacological intervention, was estimated at €37 billion out of which costs of treating fractures represented 66%, pharmacological prevention 5% and long term fracture care 29%. The total health burden was estimated at 1 180 000 lost Quality Adjusted Life Years (QALY) for the EU. The total cost in the EU might rise from €98 billion in 2010 to €120 billion Euro in 2025. The use of osteoporosis drugs has increased considerably. Approved pharmacological interventions (bisphosphonates, strontium ranelate, raloxifene, denosumab and parathyroid hormone peptides) are widely available but their use is restricted by reimbursement policies. Alendronate (a bisphosphonate) is the most commonly prescribed agent, accounting for approximately a quarter of the total value of sales. The potential users/partners are pharmaceutical companies, excluding pure generic companies (lacking development resources, relevant lobbying and sales channel to the policy makers and practitioner) selling drugs in the indication osteoporosis

Radoslaw Rudz posted this:
Licensing Manager at Centre Technology Transfer CITTRU

Mesenchymal Stem Cells (MSCs) are multipotent precursor cells with the unique capacity to self-renew, proliferation and transformation into specialized cells present in many body tissues, such as muscle, adipose tissue, fibroblasts, cartilage, tendons, and nervous tissue. They are also characterized by the ability to affect the immune system by secretion of compounds that support the immune response directed among others against bacteria and parasites. They have properties enabling the secretion of chemical compounds that stimulate the formation of new blood vessels. All these attributes make them applicable in regenerative medicine, transplantology and in the treatment of many diseases. The umbilical cord blood and Wharton’s jelly MSCs are the sources from which MSCs are obtained. Due to the small amount of MSCs in the starting material, it is necessary to lead in vitro cultures to obtain sufficient numbers of cells that can be administered to the patient. Methods of isolation and culture of mesenchymal stem cells, including the growth medium, play a crucial role in obtaining the appropriate biological material that guarantees therapeutic success. Therefore, continuous improvement of procedures for isolating and in vitro culturing of MSCs is extremely important. The subject of the offer is a method of culturing mesenchymal stem cells using secretions from carnivorous plants, which increase cell adherence and proliferation, counteract their transformation into specialized cells, therefore, they longer maintain their pluripotency.
Improving stem cell culture using carnivorous plants